GLP-1 PERIOPERATIVE GUIDE
GLP-1 Before Surgery: Should You Stop Ozempic, Wegovy, Mounjaro, or Zepbound? (2026 Guide)
Published: · Last reviewed:
Last verified: by The RX Index editorial team. This is patient education, not personal medical advice — your surgical, anesthesia, and prescribing teams have the final word for your procedure.
This page is informational and not medical advice.
Follow your surgeon's and anesthesiologist's instructions for your procedure. If your team's instructions conflict with anything here, follow your team — and feel free to ask them about the questions this page raises.
For GLP-1 before surgery, the bottom line is this: most people on a GLP-1 medication do not need to stop it before elective surgery. That's the current October 2024 multi-society guidance from five U.S. surgical and medical societies — anesthesiology, gastroenterology, bariatric surgery, perioperative obesity care, and gastrointestinal endoscopic surgery.
The answer changes if you started or increased your dose in the last 4–8 weeks, you have stomach symptoms right now (nausea, vomiting, abdominal pain, constipation), you take a high dose, you're on a weekly formulation, or you have a condition that already slows your stomach like gastroparesis or Parkinson's. Higher-risk patients may need a 24-hour liquid diet, an anesthesia-plan change, gastric ultrasound, full-stomach precautions, a one-dose hold, or rare delay — your anesthesia team decides which.
If you've been told to stop for a week, two weeks, or four weeks — that advice is out there because the original 2023 guidance said "stop for a week," and a lot of surgical offices haven't caught up to the October 2024 update. Here's what's actually true today, what your real risk tier looks like, and the exact script to use with your surgical team.
What we actually verified
We pulled this page directly from primary sources:
- The October 2024 multi-society guidance from the American Society of Anesthesiologists (ASA), American Gastroenterological Association (AGA), American Society for Metabolic and Bariatric Surgery (ASMBS), International Society of Perioperative Care of Patients with Obesity (ISPCOP), and the Society of American Gastrointestinal and Endoscopic Surgeons (SAGES), published in Surgical Endoscopy.
- The November 2024 FDA-approved class-label updates that added pulmonary aspiration warning language to GLP-1 receptor agonist labels, verified through DailyMed and accessdata.fda.gov.
- Four other society documents — ASA 2023, SPAQI 2025, the UK 2025 multi-society consensus, and the 2026 Brazilian SBD/SBA/ABESO joint position statement.
- The 2026 OCULUS randomized clinical trial (JAMA Internal Medicine) — the first head-to-head trial comparing holding vs. continuing one dose before endoscopy.
- The 2024 Aschen et al. study (Annals of Surgery) covering 74,425 surgical procedures in patients with diabetes.
- The 2024 Sen et al. study (JAMA Surgery) on residual gastric content with GLP-1 use.
- The 2025 Wright et al. analysis of 392,065 elective surgical patients on aspiration rates.
- DailyMed prescribing information for each medication for half-lives, dose-escalation rules, and label warnings.
We re-verify every item in the comparison tables every 90 days. Next scheduled re-verification: .
Quick answer: Stop or continue?
Source: October 2024 multi-society guidance (Kindel et al., Surgical Endoscopy 2024)
| Your situation | What to plan for | What to do today |
|---|---|---|
| Stable dose, no GI symptoms, elective procedure with low-aspiration anesthesia plan | Most likely continue under 2024 guidance | Tell your team your drug, dose, and last-dose date |
| New start or dose increase in the last 4–8 weeks | Likely a 24-hour liquid diet, possibly a one-dose hold | Call pre-op anesthesia at least 1–2 weeks out |
| Active nausea, vomiting, constipation, or bloating | Expect a hold, modified plan, or delay | Don't fast-and-hope — call your team now |
| High dose | 24-hour liquid diet at minimum | Confirm in writing with anesthesia |
| Gastroparesis, Parkinson's, or known motility issue | Individualized plan, possibly with gastric ultrasound | Coordinate prescriber and anesthesia |
| Emergency surgery | Treated as "full stomach" regardless | Disclose your GLP-1 the moment you can |
Do you need to stop a GLP-1 before surgery?
Most people don't need to stop. The October 2024 multi-society guidance — endorsed by anesthesiology, gastroenterology, bariatric surgery, and obesity-medicine groups — supports continuing your GLP-1 before elective surgery and endoscopy in most cases. Higher-risk patients need a tailored plan that may include a 24-hour liquid diet, an anesthesia-plan adjustment, gastric ultrasound, a one-dose hold, or in rare cases postponement.
This is a real reversal. From June 2023 until October 2024, the standard advice patients heard was: if you take a weekly GLP-1, stop it one week before surgery; if it's daily, hold it the day of. That was the original ASA consensus guidance. It made sense at the time — there were case reports of patients aspirating during surgery despite normal fasting, and slow-emptying stomachs were the suspected cause. The ASA put a cautious rule in place while the data caught up.
Then the evidence base and society positions changed. Larger observational studies didn't show a clear increase in aspiration events, while residual stomach contents remained a real signal. Endocrinologists and bariatric specialists also pointed out that stopping a GLP-1 for a week — especially in someone with diabetes — has its own real risks, including blood-sugar spikes, lost weight progress, and the hassle of dose re-titration. So in October 2024, five major societies got together and reversed the blanket "always stop" rule. Most people can continue. The real decision is risk-tiering.
If your surgical office told you to stop for a week, that's the 2023 guidance. It's not wrong, exactly — it's just out of date. Many institutional protocols update on annual cycles, and a lot haven't caught up. You're not crazy. The guidance changed.
How do GLP-1 medications affect anesthesia?
GLP-1 receptor agonists slow gastric emptying — the rate at which food and liquid leave your stomach — as part of how they work. During general anesthesia or deep sedation, slower emptying can leave residual stomach contents that raise the theoretical risk of pulmonary aspiration. Studies show residual contents are meaningfully more common in GLP-1 users; large studies of actual aspiration events show rates barely different from non-users.
Two specific mechanisms are at play. First, GLP-1 (glucagon-like peptide-1) is a natural gut hormone, and the medications mimic its signaling — including activation of the "ileal brake," a mechanism that slows the stomach to give the small intestine time to absorb nutrients. Second, GLP-1s can blunt the normal response that empties the stomach during a meal, particularly in the first weeks of treatment.
During anesthesia, two things change about your body's defense against aspiration: airway reflexes are reduced, and the muscles that normally keep stomach contents from refluxing relax. If solid food or liquid is still in the stomach when that happens, regurgitation becomes more likely. That's the entire reason fasting before surgery exists, and it's the reason GLP-1s drew attention in the first place.
The honest data picture
Clinically significant residual gastric volume (upper endoscopy)
2026 OCULUS randomized trial (N=60) — continued GLP-1 vs. held one dose · JAMA Internal Medicine
Increased residual gastric content on ultrasound (fasted patients)
Sen et al. 2024 (N=124) — GLP-1 users vs. non-users · JAMA Surgery
Actual pulmonary aspiration rates (elective surgery, largest study)
Wright et al. 2025 (N=392,065 patients, 15,745 GLP-1 users) — no significant difference after adjustment · International Journal of Surgery
Residual contents are a precursor risk that anesthesia teams can manage with technique. Aspiration is the dangerous outcome, and it remains uncommon. That's the gap between "real concern, manage carefully" and "always stop, no exceptions."
What changed in October 2024
In October 2024, the ASA, AGA, ASMBS, ISPCOP, and SAGES jointly published new guidance reversing the 2023 "stop weekly GLP-1s for one week" rule. The updated guidance says most patients can continue, with risk-stratified protocols for higher-risk patients. The FDA followed in November 2024 with class-label updates that added pulmonary aspiration warning language to GLP-1 prescribing information — but did not require any specific stop-time.
ASA original consensus
Hold daily GLP-1s the day of surgery, hold weekly GLP-1s for a week. This rule shows up everywhere.
AGA pushes back
AGA states there's no good data to support a blanket stop before endoscopy.
Evidence accumulates
A pooled analysis estimated a mean solid-phase gastric-emptying delay of about 36 minutes — small relative to the standard 6-hour fasting window. JAMA Surgery publishes Sen et al. showing residual contents are higher with GLP-1 use, while large claims-based studies don't show meaningfully higher actual aspiration.
Five-society reversal
ASA + AGA + ASMBS + ISPCOP + SAGES publish joint guidance: most patients can continue. Risk-stratify the rest.
FDA class-label updates
FDA adds pulmonary aspiration warning language to GLP-1 receptor agonist labels (semaglutide, tirzepatide, dulaglutide, liraglutide, exenatide). The warning instructs patients to inform their providers — it does not mandate stopping.
New trials sharpen the picture
OCULUS randomized trial (2026) shows residual gastric content is meaningfully higher in patients who continued vs. held one dose for upper endoscopy. A 2026 systematic review estimated mean gastric-emptying half-time prolongation of about 74 minutes — with very-low-certainty evidence, meaning the size of the delay is still not fully settled.
What the FDA label actually says
The current Ozempic label states that rare postmarketing pulmonary aspiration has been reported in GLP-1 users undergoing general anesthesia or deep sedation despite fasting, and that available data are insufficient to determine whether changing fasting recommendations or temporarily stopping the medication reduces risk. The FDA didn't tell anyone to stop — it told patients to disclose. That's a different message than "stop for a month."
How the major societies actually compare
Five major society documents have addressed this since 2023, and they don't all agree. The October 2024 U.S. multi-society document is the most influential framework in U.S. practice today, but the 2025 SPAQI consensus, the 2025 UK consensus, and the 2026 Brazilian joint position each take different stances.
| Society | Year | Recommendation | Liquid diet stance |
|---|---|---|---|
| American Society of Anesthesiologists (ASA) — original | Jun 2023 | Hold daily GLP-1s on day of surgery; hold weekly GLP-1s 1 week before — regardless of dose, indication, or procedure | Not addressed |
| U.S. multi-society joint guidance (ASA + AGA + ASMBS + ISPCOP + SAGES) | Oct 2024 | Most patients can continue. Hold only when elevated-risk profile is present. When holding is indicated, follow original ASA timing. | 24-hour liquid diet for elevated-risk patients |
| SPAQI consensus (Society for Perioperative Assessment & Quality Improvement) | 2025 | Continue GLP-1 RAs in patients without significant GI symptoms; delay elective procedures for significant GI symptoms | 24-hour fast from solids; clear liquids allowed |
| UK multi-society consensus (Centre for Perioperative Care + Association of Anaesthetists + Royal College of Anaesthetists + JBDS + others) | 2025 | Continue GLP-1s throughout the perioperative period; manage aspiration risk via shared decision-making, fasting, and anesthesia technique | Not standard |
| Brazilian joint position (SBD + SBA + ABESO) | 2026 | When discontinuation is indicated: withhold long-acting GLP-1/GIP-GLP-1 agents 7 days before; withhold short-acting agents 1 day before | 24-hour liquid diet alongside fasting |
The U.S. multi-society 2024 guidance is the framework you'll most often hear from U.S. anesthesiologists today. SPAQI and the UK consensus are also permissive about continuation. The 2026 Brazilian joint position is more conservative when discontinuation is chosen, but its 7-day window for long-acting agents is closer to the original ASA rule than the older "three half-lives" guidance you may still see online.
None of these is "wrong" — they're applying different risk philosophies to imperfect data. Your hospital may have its own protocol that's stricter than any of them for institutional reasons, and that protocol wins for your specific procedure.
Why your dose, your symptoms, and your surgery type matter more than the calendar
The October 2024 multi-society guidance identifies five risk factors that change the plan: (1) the dose-escalation phase, (2) higher dose, (3) weekly versus daily formulation, (4) current GI symptoms, and (5) any condition that already slows gastric emptying. Patients with none of these can typically continue. Patients with one or more usually need a 24-hour liquid diet, an anesthesia-plan adjustment, or both.
Dose escalation — the first 4–8 weeks
When you start a GLP-1 — or step up to a higher dose — your stomach reacts strongly. That's the same reason most people feel nausea, fullness, or constipation in the first month or two. Studies consistently show this is when delayed gastric emptying is most pronounced. Once you're stable on a dose, your stomach adapts (tachyphylaxis), and the emptying delay shrinks.
Higher dose
Higher doses produce stronger effects across the board, including stronger emptying delays. The 2024 guidance uses 'high dose' as a risk variable but does not give a single universal cutoff across all GLP-1s — your team decides whether your current dose qualifies based on the maintenance dose for your specific medication.
Weekly vs. daily formulation
GI side effects are more common with weekly than with daily formulations. But daily dosing doesn't always mean a short-half-life drug — Rybelsus is oral semaglutide, and semaglutide still has a half-life of about a week regardless of how it's taken. Skipping one daily pill doesn't mean the drug is gone; it means the formulation timing has been adjusted.
Current GI symptoms
Nausea, vomiting, constipation, abdominal bloating, or indigestion are direct signals that gastric emptying is already slow right now — not just theoretically. If you have any of these, your anesthesia team almost certainly wants to know before surgery, and 'just fast longer' is not an adequate management plan.
Dysmotility comorbidities
Gastroparesis, Parkinson's disease, autonomic neuropathy, and certain other conditions independently slow gastric emptying. Adding a GLP-1 on top creates a compounded risk. Patients with these conditions need individualized plans, and gastric-content ultrasound on the morning of surgery is a tool that may be offered where available.
Stop times by medication — if your team decides a hold is indicated
The table below shows the hold timing specified in the original 2023 ASA guidance (still used when a hold is clinically indicated under the 2024 framework) and the Brazilian 2026 position. "Continue" is the default for low-risk patients under the 2024 U.S. multi-society guidance. Source: ASA 2023; Brazilian SBD/SBA/ABESO 2026; DailyMed prescribing information.
| Brand (generic) | Dosing schedule | Half-life | Hold time (ASA 2023 / if indicated) |
|---|---|---|---|
| Ozempic (semaglutide) | Weekly injection | ~7 days | Skip the dose 1 week before surgery (if hold indicated); continue for low-risk |
| Wegovy (semaglutide) | Weekly injection | ~7 days | Skip the dose 1 week before surgery (if hold indicated); continue for low-risk |
| Rybelsus (oral semaglutide) | Daily pill | ~7 days | Hold morning-of dose (if hold indicated); continue the day-before dose for low-risk |
| Mounjaro (tirzepatide) | Weekly injection | ~5 days | Skip the dose 1 week before surgery (if hold indicated); continue for low-risk |
| Zepbound (tirzepatide) | Weekly injection | ~5–6 days | Skip the dose 1 week before surgery (if hold indicated); continue for low-risk |
| Trulicity (dulaglutide) | Weekly injection | ~5 days | Skip the dose 1 week before surgery (if hold indicated); continue for low-risk |
| Saxenda (liraglutide) | Daily injection | ~13 hours | Hold day of surgery (if hold indicated) |
| Victoza (liraglutide) | Daily injection | ~13 hours | Hold day of surgery (if hold indicated) |
| Byetta (exenatide) | Twice daily | ~2.4 hours | Hold day of surgery (if hold indicated) |
| Foundayo (orforglipron) | Daily pill | ~29–49 hours | Hold day of surgery (if hold indicated); confirm with team as perioperative data are limited |
Source: ASA 2023 consensus guidance; October 2024 U.S. multi-society guidance; Brazilian SBD/SBA/ABESO 2026; DailyMed prescribing information (Ozempic, Wegovy, Mounjaro, Zepbound, Trulicity, Saxenda, Victoza, Byetta). Half-lives sourced from FDA-approved prescribing information. "If hold indicated" means your team has determined a hold is appropriate based on your risk profile under the 2024 framework.
Related: How long does each GLP-1 actually stay in your system?
Half-life charts for Ozempic, Wegovy, Mounjaro, Zepbound, Trulicity, Saxenda, and Foundayo — including clearance curves and missed-dose rules from FDA prescribing information.
GLP-1 Half-Life & Clearance Chart →What to tell your surgical team
Disclose your GLP-1 early — ideally when you schedule surgery, or at minimum at your pre-op appointment. The team needs your drug name, dose, dosing schedule, how long you've been at this dose, your last-dose date, and whether you currently have GI symptoms.
Here's the disclosure script in one paragraph — copy it directly into the patient portal message or say it to your pre-op nurse:
"I take [medication name and dose — e.g., Ozempic 1 mg weekly / Wegovy 2.4 mg weekly / Mounjaro 10 mg weekly]. I've been on this dose for [X weeks/months] and my last dose was [date]. I [do / don't] currently have any nausea, vomiting, abdominal pain, constipation, or bloating."
That gives them everything they need in one paragraph. It also signals you've done your homework, which usually means you'll get a more detailed answer back.
The five questions to actually ask:
- "Based on my risk factors, do you want me to continue or hold my GLP-1?"
- "Do I need a 24-hour liquid diet, and when does it start?"
- "If I'm holding the medication and I'm diabetic, what's my blood sugar plan during the hold?"
- "When and how should I restart after surgery?"
- "If something changes — I get nauseated, I forget and take a dose — who do I call and what number?"
What to do if you accidentally took your GLP-1 close to surgery
Tell your team. Don't hide it. Depending on your risk and the procedure, the team may proceed with precautions, check gastric contents with point-of-care ultrasound when available, change the anesthesia plan, treat you as a full-stomach patient, switch to a 24-hour liquid diet, or reschedule. Hiding the dose is the only outcome that's actually unsafe.
Call the pre-op number as soon as you realize. The script is short:
"I'm scheduled for [procedure] on [date]. I take [medication and dose]. I took my dose on [date and time]. I [do / don't] currently have GI symptoms. What should I do?"
Point-of-care gastric ultrasound is a key modern tool — when trained staff and equipment are available, the anesthesiologist can assess your stomach contents the morning of surgery. If results are clearly empty, the case may proceed as planned. If results are concerning or unclear, the team may delay, use full-stomach precautions, or change the anesthesia plan.
The thing that gets people in trouble isn't taking a dose by accident. It's not telling anyone.
Why you're getting different instructions from different doctors
Different instructions happen because (1) the guidance genuinely changed in October 2024 and not every provider's office has updated, (2) hospitals and surgery centers can be stricter than national guidance for liability or workflow reasons, (3) procedure-specific data moves faster than general guidance, and (4) different specialties weigh aspiration risk versus glycemic control differently. Your anesthesiologist usually has the deciding vote.
Surgeon says X, prescriber says Y
Surgeons are thinking about the day of surgery; prescribers are thinking about your blood sugar and treatment continuity. Both are right within their lane. The anesthesiologist makes the final call on perioperative timing.
Old guidance vs. new
If your surgeon's office is still quoting the 2023 "stop for a week" rule, you can ask: "Has your protocol updated to the October 2024 multi-society guidance, or do you want me to follow the older 2023 ASA approach?" That question alone often surfaces whether the office has reviewed it.
National guidance vs. hospital protocol
Your hospital's protocol wins for your specific procedure. They've made an institutional risk decision. You can ask why, but if the answer is "it's our protocol," follow it.
If you're getting truly contradictory instructions and your surgery is more than a week away, request a pre-op anesthesia consultation. Most hospitals will set one up, especially for patients with complex medications. It's a 30-minute conversation with the person who's actually responsible for your airway during surgery.
How to restart your GLP-1 after surgery
Restart timing depends on your procedure, your symptoms, your bowel function, your glucose plan, and the missed-dose rules for your specific medication — not a single universal clock. Ask your prescriber and surgical team when to restart once you can tolerate your usual diet. If you missed Saxenda for more than 3 days, the FDA label requires you to restart at 0.6 mg/day and re-titrate.
Key checkpoints before you restart:
- Can you eat and drink normally?
- Has nausea cleared?
- Is your bowel function back?
- If diabetic: how has your blood sugar been during the hold, and has your prescriber adjusted your other medications?
Saxenda re-titration rule
Per FDA prescribing information: if more than 3 days have passed since the last Saxenda dose, restart at 0.6 mg/day and follow the original escalation schedule. Other GLP-1s don't have a hard label rule for missed doses, but the same principle applies — confirm your specific restart plan with your prescriber, ideally before surgery while you have time to remember it.
When to call the prescriber after surgery:
- Persistent nausea or vomiting beyond expected post-op recovery
- Worsening abdominal pain (separate from incision pain)
- Inability to keep liquids down
- Blood sugar swings that aren't responding to your usual plan
What to do based on when your surgery is
The right action depends on how much time you have. With more than 2 weeks, you have time to coordinate prescriber and anesthesia and confirm everything in writing. Within 7 days, call pre-op now. Within 24 hours, call the day-of-surgery number — don't manage it alone.
More than 2 weeks away
- Write down your medication, dose, dosing schedule, last dose date, and any current GI symptoms.
- Call your surgical office and ask for written pre-op instructions for GLP-1 patients specifically.
- If you're diabetic, separately call your prescriber and ask whether stopping or modifying the GLP-1 around surgery affects your blood sugar plan.
- Ask both teams to coordinate or share notes via your patient portal.
- Confirm your restart plan now, before surgery, while you have bandwidth to remember it.
Within 7 days
- Call pre-op. Don't wait for them to call you.
- Use the disclosure script above.
- If you've gotten conflicting instructions, ask for a pre-op anesthesia consultation today.
Within 24–48 hours
- Call the day-of-surgery number on your pre-op paperwork.
- Tell them everything.
- Don't make changes to your medication on your own this close to surgery — call and ask.
Surgery is tomorrow
- Call the pre-op number now.
- If after hours, follow your facility's instructions and disclose the medication at check-in.
- Don't skip the disclosure to avoid getting cancelled — the cancellation is the recoverable outcome; an undisclosed aspiration is not.
Active vomiting, severe abdominal pain, or can't keep liquids down
- This isn't a medication-management question — it's an evaluation question.
- Call your surgical or anesthesia team's urgent line.
- For severe symptoms (persistent vomiting, severe pain, dehydration), use emergency care.
Worried about losing weight progress during a hold?
Most people who hold a GLP-1 for 1–2 weeks see some appetite return but not complete weight regain. Here's what the evidence says about what happens at a plateau — and after stopping.
GLP-1 Weight Loss Plateau: What to Expect →Frequently asked questions
Should I stop Ozempic one week before surgery?
Not automatically. The 2023 ASA guidance said yes for weekly GLP-1s. The October 2024 multi-society guidance — which superseded it for most U.S. practice — says most patients can continue. If you're elevated risk (escalation phase, high dose, GI symptoms, or motility comorbidity), your team may still ask for a 7-day hold plus a 24-hour liquid diet. Confirm with your specific surgical team.
Is it safe to have anesthesia while on a GLP-1?
For most patients in maintenance phase without GI symptoms, yes. The October 2024 multi-society guidance explicitly endorses continuing the medication in low-risk patients. Risk-stratified patients require additional precautions, but anesthesia remains safe with appropriate planning. The honest data: aspiration rates in GLP-1 users undergoing elective surgery were 0.8% versus 0.7% in non-users in the largest claims analysis to date — not a statistically significant difference.
Can I just have a colonoscopy without stopping?
For colonoscopy specifically, many GI teams allow continued GLP-1 use because the standard clear-liquid bowel prep already minimizes residual stomach contents. The 2026 OCULUS subgroup analysis showed no clinically significant gastric residue in patients having both EGD and colonoscopy on a clear-liquid prep day, regardless of whether they held the medication. Ask your gastroenterologist for their specific protocol.
What if my surgeon and my prescriber disagree about stopping my GLP-1?
Both opinions are usually valid given the conflicting society documents. Your anesthesiologist gets the deciding vote because they're responsible for airway management during the procedure. Request a pre-op anesthesia consultation if there's a real disagreement and surgery is more than a few days out.
Will my surgery get cancelled if I take my GLP-1 dose by accident?
Maybe. The team may proceed with precautions, check gastric contents with point-of-care ultrasound if available, change the anesthesia plan, switch to a 24-hour liquid diet, or reschedule — especially if the procedure is non-urgent and you have active GI symptoms. Disclose immediately so your team can decide proactively.
Are compounded GLP-1s treated differently before surgery?
Tell anesthesia which molecule the compound contains (semaglutide or tirzepatide), the dose you've been told to use, and your last-dose date. Your team will apply the same gastric-emptying risk questions. Worth knowing: compounded GLP-1s aren't FDA-approved products, and compounded potency and bioavailability can vary, so be precise about your dose.
Should I stop my GLP-1 before a tooth extraction?
For local anesthesia or minimal sedation, usually no. For IV sedation or general anesthesia, treat it as you would any other surgery — disclose, apply the risk-tier framework, follow your team's protocol. The deciding question is the depth of sedation, not the procedure name.
Why does my anesthesiologist say one thing and my surgeon's office said another?
Because U.S. society guidance is genuinely split and individual practices update protocols on different schedules. The 2023 ASA 'stop for a week' guidance is still in many institutional handbooks; the October 2024 multi-society reversal is what most academic-center anesthesiologists now reference. Your anesthesiologist usually has the more current view, but your surgical center's protocol governs your specific case.
How long does Ozempic stay in your system?
Semaglutide has a half-life of about 7 days, which means meaningful drug levels persist for roughly 5 weeks after the last dose. The gastric-emptying effect normalizes well before the drug fully clears — most studies suggest emptying returns to near-normal within 1–2 weeks for most users.
Can I still take my Rybelsus the morning of surgery?
The 2024 multi-society guidance treats daily formulations as 'hold the day of surgery' if a hold is indicated. For most low-risk patients, continuing the previous day's dose is acceptable, and only the morning-of dose is held. Confirm with your team.
What if I take my GLP-1 for diabetes — won't stopping spike my blood sugar?
This is exactly the concern that drove the October 2024 reversal. Stopping a GLP-1 in a diabetic patient creates its own risks, including hyperglycemia and worse perioperative metabolic control. The 2024 guidance specifically says the team should balance aspiration risk against the metabolic risk of stopping. If your team wants you to hold, ask for a specific glucose plan: monitoring frequency, medication adjustments, and who to call for high or low readings.
Sources and methodology
Primary sources cited on this page:
- Kindel TL, Wang AY, Wadhwa A, et al. Multi-society clinical practice guidance for the safe use of glucagon-like peptide-1 receptor agonists in the perioperative period. Surgical Endoscopy. 2024;39(1):180–183.
- American Society of Anesthesiologists. Most patients can continue diabetes and weight loss GLP-1 drugs before surgery. ASA news release, October 29, 2024.
- American Gastroenterological Association. Most patients can continue GLP-1 anti-obesity drugs before surgery. AGA news release, October 30, 2024.
- ASA. Consensus-based guidance on preoperative management of patients on GLP-1 receptor agonists. June 29, 2023.
- FDA / DailyMed. Class-label updates adding pulmonary aspiration warning language to GLP-1 receptor agonist prescribing information, November 2024.
- Society for Perioperative Assessment and Quality Improvement (SPAQI). Consensus statement on perioperative GLP-1 management. British Journal of Anaesthesia, 2025.
- UK multi-society consensus on elective perioperative management of adults taking GLP-1 receptor agonists. Centre for Perioperative Care, Association of Anaesthetists, Royal College of Anaesthetists, Joint British Diabetes Societies. 2025.
- Brazilian Society of Diabetes (SBD), Brazilian Society of Anesthesiology (SBA), and Brazilian Association for the Study of Obesity and Metabolic Syndrome (ABESO). Joint position statement on perioperative screening and management of hyperglycemia in patients on GLP-1/GIP-GLP-1 receptor agonists. Diabetology & Metabolic Syndrome, 2026.
- Ahmad AI, Garg S, Jacobs J, et al. Holding vs continuing GLP-1/GIP agonists before upper endoscopy: the OCULUS randomized clinical trial. JAMA Internal Medicine. 2026.
- Aschen SZ, Zhang A, O'Connell GM, et al. Association of perioperative glucagon-like peptide-1 receptor agonist use and postoperative outcomes. Annals of Surgery. 2025;281(4):600–607.
- Wright JD, Chen L, Xu X, et al. GLP-1 receptor agonist use and the risk of pulmonary aspiration in patients undergoing surgery. International Journal of Surgery. 2025.
- Sen S, Potnuru PP, Hernandez N, et al. GLP-1 receptor agonist use and residual gastric content before anesthesia. JAMA Surgery. 2024;159:660–667.
- AAOS 2025 Annual Meeting. New study recommends stopping GLP-1 agonists 14 days before total joint arthroplasty.
- DailyMed prescribing information: Ozempic, Wegovy, Rybelsus, Mounjaro, Zepbound, Trulicity, Saxenda, Victoza, Byetta.
We compiled this guidance directly from each society's published documents and the FDA's prescribing-information database. Where guidance differs across societies, we presented each position with attribution rather than picking a single "right" answer. Where evidence is limited or contested, we said so. We re-verify every item in the comparison tables every 90 days.
Spot a stale fact or broken source link? Email corrections@therxindex.com — we update on the next 90-day cycle.
Last verified: · Next scheduled re-verification: